Lantheus (LNTH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Oct, 2026Executive summary
Merger Agreement signed Aug. 3, 2026: Merger Sub will merge into the issuer, which will survive as a wholly owned subsidiary of Parent, subject to closing conditions.
Supplemental proxy disclosures were issued amid merger-related litigation; the issuer denied the proxy was deficient and said disclosures were made without admitting liability or wrongdoing.
Voting matters and shareholder proposals
A special meeting is scheduled for Oct. 14, 2026, to vote on the Merger Agreement and related proposals.
Board of directors and corporate governance
Three lawsuits filed against the issuer and certain directors alleged proxy omissions or misstatements involving projections, Morgan Stanley’s fairness analyses and insider conflicts; plaintiffs seek to enjoin the merger pending further disclosure.
As of Sept. 30, 2026, 16 stockholder demand letters had been received, including two with draft complaints; additional demands or lawsuits may follow.
Latest events from Lantheus
- Merger with Curium US Holdings LLC advances, pending regulatory and shareholder approval.LNTH
Proxy filing - Stockholders are urged to approve the proposed merger with Curium US Holdings LLC.LNTH
Proxy filing - Shareholders to vote on $102.50 cash plus CVR merger; board unanimously recommends approval.LNTH
Proxy filing - Shareholders to vote on merger creating a global radiopharmaceutical leader, closing in 2027.LNTH
Proxy filing - Q2 2026 revenue up 2.7%, adjusted EPS $1.55, and merger with Curium valued up to $8B announced.LNTH
Q2 2026 - Curium and Lantheus announce a merger to create a global leader in diagnostics and therapeutics.LNTH
Proxy filing - Shareholders to receive $102.50 per share plus up to $12.00 in CVRs, pending milestone achievements.LNTH
Proxy filing - Definitive merger agreement with Curium offers up to $114.50 per share, closing expected in H1 2027.LNTH
Proxy filing - Curium to acquire Lantheus for up to $114.50/share, creating a global radiopharmaceutical leader.LNTH
Proxy filing